Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Weight-Loss drug AZD5004 tested in chinese adults

NCT ID NCT06988553

Symptom relief Sponsor: Eccogene Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called AZD5004 in 45 Chinese adults who were overweight or had obesity, with or without type 2 diabetes. The main goal was to check if the drug is safe and how the body processes it, compared to a placebo. Participants took the drug or a dummy pill, and researchers monitored side effects and drug levels in the blood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

45 people

The number who actually took part.

Started

Jun 2025

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 74 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 to 74 years inclusive at the time of signing the informed consent. * Stable self-reported body weight for 3 months prior to Screening. Inclusion Criteria for Cohort A: \- 27 kg/m2 ≤ BMI ≤ 35 kg/m2 and weigh at least 60 kg at Screening. Inclusion Criteria for Cohort B: * Diagnosed with T2DM for at least 6 months prior to signing the informed consent. * HbA1c value at Screening of ≥ 7.0% and ≤ 10.5% * BMI of ≥ 24 kg/m2 at the Screening Visit. Exclusion Criteria: * History of, or any existing condition that influence the participant's ability to participate or affect the interpretation of the results of the study. * Known clinically significant gastric emptying abnormality. * Significant hepatic disease. * Abnormal renal function. * History of acute pancreatitis and chronic pancreatitis, gallstones. * Uncontrolled thyroid disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity or overweight Type 2 diabetes

Contacts and locations

Locations

  • General Hospital of Tianjin Medical University

    Tianjin, China

  • Jinan Central Hospital

    Jinan, China

  • Shanghai Pudong New District People's Hospital

    Shanghai, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    Ha’erbin, China

  • The Second People's Hospital of Hefei

    Hefei, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.